Pharmacokinetics, tissue distribution and relative bioavailability of puerarin solid lipid nanoparticles following oral administration. 2011

Cheng-Feng Luo, and Mu Yuan, and Min-Sheng Chen, and Shi-Ming Liu, and Liu Zhu, and Bi-Yun Huang, and Xia-Wen Liu, and Wen Xiong
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Cardiovascular Disease, Guangzhou 510260, China.

Puerarin has various pharmacological effects; however, poor water-solubility and low oral bioavailability limit its clinical utility. A delivery system of solid lipid nanoparticles could enhance its oral absorption. The objective of this study was to investigate the pharmacokinetics, tissue distribution and relative bioavailability of puerarin in rats after a single dose intragastric administration of puerarin solid lipid nanoparticles (Pue-SLNs). The puerarin concentrations in plasma and tissues were determined by rapid resolution liquid chromatography electrospray ionization-tandem mass spectrometry. The C(max) value of puerarin after the administration of Pue-SLNs was significantly higher than that obtained with puerarin suspension (0.33±0.05 μg/mL vs. 0.16±0.06 μg/mL, P<0.01). The T(max) value after the administration of the Pue-SLNs was significantly shorter than that after puerarin suspension administration (40±0 min vs. 110±15.49 min, P<0.01). The AUC(0→t) values of puerarin were 0.80±0.23 mg h/L, and 2.48±0.30 mg h/L after administration of the puerarin suspension and Pue-SLNs, respectively. Following administration of the Pue-SLNs, tissue concentrations of puerarin also increased, especially in the target organs such as the heart and brain. These data suggest that SLNs are a promising delivery system to enhance the oral bioavailability of puerarin.

UI MeSH Term Description Entries
D007529 Isoflavones 3-Phenylchromones. Isomeric form of FLAVONOIDS in which the benzene group is attached to the 3 position of the benzopyran ring instead of the 2 position. 3-Benzylchroman-4-One,3-Benzylidene-4-Chromanone,Homoisoflavone,Homoisoflavones,Isoflavone,Isoflavone Derivative,3-Benzylchroman-4-Ones,3-Benzylidene-4-Chromanones,Isoflavone Derivatives,3 Benzylchroman 4 One,3 Benzylchroman 4 Ones,3 Benzylidene 4 Chromanone,3 Benzylidene 4 Chromanones,Derivative, Isoflavone,Derivatives, Isoflavone
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D008297 Male Males
D002853 Chromatography, Liquid Chromatographic techniques in which the mobile phase is a liquid. Liquid Chromatography
D005260 Female Females
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D014018 Tissue Distribution Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios. Distribution, Tissue,Distributions, Tissue,Tissue Distributions
D014665 Vasodilator Agents Drugs used to cause dilation of the blood vessels. Vasoactive Antagonists,Vasodilator,Vasodilator Agent,Vasodilator Drug,Vasorelaxant,Vasodilator Drugs,Vasodilators,Vasorelaxants,Agent, Vasodilator,Agents, Vasodilator,Antagonists, Vasoactive,Drug, Vasodilator,Drugs, Vasodilator

Related Publications

Cheng-Feng Luo, and Mu Yuan, and Min-Sheng Chen, and Shi-Ming Liu, and Liu Zhu, and Bi-Yun Huang, and Xia-Wen Liu, and Wen Xiong
January 2014, Journal of microencapsulation,
Cheng-Feng Luo, and Mu Yuan, and Min-Sheng Chen, and Shi-Ming Liu, and Liu Zhu, and Bi-Yun Huang, and Xia-Wen Liu, and Wen Xiong
January 2013, International journal of pharmaceutics,
Cheng-Feng Luo, and Mu Yuan, and Min-Sheng Chen, and Shi-Ming Liu, and Liu Zhu, and Bi-Yun Huang, and Xia-Wen Liu, and Wen Xiong
October 2005, Journal of controlled release : official journal of the Controlled Release Society,
Cheng-Feng Luo, and Mu Yuan, and Min-Sheng Chen, and Shi-Ming Liu, and Liu Zhu, and Bi-Yun Huang, and Xia-Wen Liu, and Wen Xiong
November 2006, Journal of drug targeting,
Cheng-Feng Luo, and Mu Yuan, and Min-Sheng Chen, and Shi-Ming Liu, and Liu Zhu, and Bi-Yun Huang, and Xia-Wen Liu, and Wen Xiong
May 2002, Journal of pharmaceutical sciences,
Cheng-Feng Luo, and Mu Yuan, and Min-Sheng Chen, and Shi-Ming Liu, and Liu Zhu, and Bi-Yun Huang, and Xia-Wen Liu, and Wen Xiong
May 1999, Pharmaceutical research,
Cheng-Feng Luo, and Mu Yuan, and Min-Sheng Chen, and Shi-Ming Liu, and Liu Zhu, and Bi-Yun Huang, and Xia-Wen Liu, and Wen Xiong
January 2023, Current pharmaceutical design,
Cheng-Feng Luo, and Mu Yuan, and Min-Sheng Chen, and Shi-Ming Liu, and Liu Zhu, and Bi-Yun Huang, and Xia-Wen Liu, and Wen Xiong
January 2013, Chinese medicine,
Cheng-Feng Luo, and Mu Yuan, and Min-Sheng Chen, and Shi-Ming Liu, and Liu Zhu, and Bi-Yun Huang, and Xia-Wen Liu, and Wen Xiong
May 2014, International journal of pharmaceutics,
Cheng-Feng Luo, and Mu Yuan, and Min-Sheng Chen, and Shi-Ming Liu, and Liu Zhu, and Bi-Yun Huang, and Xia-Wen Liu, and Wen Xiong
November 2011, Expert opinion on drug delivery,
Copied contents to your clipboard!